IL6 and anemia (phenotype): Treatment-induced tissue damage elevates circulating mediators (C-reactive protein [CRP], IL-6, interleukin-1β [IL-1β], interferon [IFN], tumor necrosis factor-α [TNF-α] potentially mediating central fatigue through anemia and cachexia pathways.45